Published in Int J Cancer on December 19, 1997
Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer (2001) 3.10
The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol (2004) 2.74
Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2003) 1.54
The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2002) 1.52
Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol (2004) 1.39
Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax (2005) 1.35
The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer (2003) 1.14
Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer (2001) 1.08
A biological staging model for operable non-small cell lung cancer. Thorax (2001) 0.95
Immunohistochemical analysis of non-small cell lung cancer: correlation with clinical parameters and prognosis. J Korean Med Sci (2007) 0.95
Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br J Cancer (2000) 0.94
bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. Clin Exp Metastasis (1999) 0.90
The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax (1999) 0.90
Prognostic significance of the combined score of endothelial expression of nucleolin and CD31 in surgically resected non-small cell lung cancer. PLoS One (2013) 0.83
Immunohistochemical analysis of Bcl-2 protein in early squamous cell carcinoma of the bronchus treated with photodynamic therapy. Br J Cancer (2000) 0.80
Neo-angiogenesis in locally advanced squamous cell head and neck cancer correlates with thymidine phosphorylase expression and p53 nuclear oncoprotein accumulation. Clin Exp Metastasis (1998) 0.79
Prognostic value of Bcl-2 expression in patients with non-small-cell lung cancer: a meta-analysis and systemic review. Onco Targets Ther (2015) 0.79
Periostin and tumor-stroma interactions in non-small cell lung cancer. Oncol Lett (2016) 0.78
A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells. Ann Thorac Cardiovasc Surg (2009) 0.78
Tumor angiogenesis, apoptosis, and p53 oncogene in stage I lung adenocarcinoma. Surg Today (1999) 0.75
A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood (1994) 21.00
Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res (2000) 5.74
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A (1997) 5.42
Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res (1996) 5.38
An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol (1994) 5.34
The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol (2000) 5.21
Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet (1990) 4.49
Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol (1990) 4.42
Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet (1987) 4.28
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology (2002) 4.22
Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet (1992) 4.10
bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med (1993) 4.05
Equilibrium properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.91
Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood (1998) 3.67
Diagnosis of human lymphoma with monoclonal antileukocyte antibodies. N Engl J Med (1983) 3.63
Ki67 protein: the immaculate deception? Histopathology (2002) 3.61
The Bloom's syndrome gene product interacts with topoisomerase III. J Biol Chem (2000) 3.52
Transferrin receptor on endothelium of brain capillaries. Nature (1984) 3.37
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res (1989) 3.35
Kinetic properties of a voltage-dependent junctional conductance. J Gen Physiol (1981) 3.33
HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res (2001) 3.27
Transferrin receptors in human tissues: their distribution and possible clinical relevance. J Clin Pathol (1983) 3.23
Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer (2001) 3.10
JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol (1990) 3.10
Monoclonal antibody Ki-67: its use in histopathology. Histopathology (1990) 3.07
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer (1996) 3.07
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax (2000) 2.83
Immunocytochemical localization of the cystic fibrosis gene product CFTR. Proc Natl Acad Sci U S A (1991) 2.82
KP1: a new monoclonal antibody that detects a monocyte/macrophage associated antigen in routinely processed tissue sections. J Clin Pathol (1989) 2.82
Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer (2002) 2.82
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 2.76
Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol (2001) 2.71
Use of monoclonal antibodies for the histopathological diagnosis of human malignancy. J Clin Pathol (1982) 2.69
Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res (2001) 2.66
Gap junctional conductance is a simple and sensitive function of intracellular pH. Science (1981) 2.64
eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol (1999) 2.57
Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. J Pathol (1995) 2.52
Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br J Cancer (1999) 2.47
Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet (1985) 2.44
Immunohistological analysis of human mononuclear phagocytes and dendritic cells by using monoclonal antibodies. Lab Invest (1986) 2.42
Peripheral T-cell lymphoma associated with hemophagocytic syndrome. Blood (1990) 2.40
Clinical importance of analysing malignant tumours of uncertain origin with immunohistological techniques. Lancet (1985) 2.40
Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res (2001) 2.38
Transient increase in phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol trisphosphate during activation of human neutrophils. J Biol Chem (1989) 2.35
c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer (1991) 2.29
Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet (1999) 2.26
Human lymphoid cells express epithelial membrane antigen. Implications for diagnosis of human neoplasms. Lancet (1984) 2.25
Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer (1996) 2.23
Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst (1993) 2.22
Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res (1994) 2.21
Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer (2003) 2.20
Association between platelet microthrombi and finger clubbing. Lancet (1991) 2.20
Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol (1997) 2.19
Expression of vascular endothelial growth factor by macrophages is up-regulated in poorly vascularized areas of breast carcinomas. J Pathol (2000) 2.18
Macrophage responses to hypoxia: relevance to disease mechanisms. J Leukoc Biol (1999) 2.17
Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol (2000) 2.11
Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol (2005) 2.10
Isoform composition of connexin channels determines selectivity among second messengers and uncharged molecules. J Biol Chem (1998) 2.08
An inositol tetrakisphosphate-containing phospholipid in activated neutrophils. Nature (1988) 2.07
Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst (1995) 2.07
Systemic endothelial activation occurs in both mild and severe malaria. Correlating dermal microvascular endothelial cell phenotype and soluble cell adhesion molecules with disease severity. Am J Pathol (1998) 2.05
Molecular cloning of ICAM-3, a third ligand for LFA-1, constitutively expressed on resting leukocytes. Nature (1992) 2.03
Secretion of epidermal growth factor by macrophages associated with breast carcinoma. Lancet (1993) 2.03
Regulation of autophagy by ATF4 in response to severe hypoxia. Oncogene (2010) 1.93
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol (2007) 1.90
Voltage dependence of junctional conductance in early amphibian embryos. Science (1979) 1.90
A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Res (1994) 1.89
Bcl-2 protein expression in follicular lymphomas in absence of 14;18 translocation. Lancet (1990) 1.86
Detection of T cells in paraffin wax embedded tissue using antibodies against a peptide sequence from the CD3 antigen. J Clin Pathol (1989) 1.85
Selectivity of connexin-specific gap junctions does not correlate with channel conductance. Circ Res (1995) 1.84
Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer (1987) 1.83
Targeting gene expression to hypoxic tumor cells. Nat Med (1997) 1.82
Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol (1995) 1.81
bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer (1994) 1.81
Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol (2000) 1.78
Cytokeratin expression in smooth muscle and smooth muscle tumours. Histopathology (1987) 1.78
The immunocytochemical detection of axillary micrometastases in breast cancer. Br J Cancer (1984) 1.77
The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer (2011) 1.77
Development and evaluation of a PCR-based immunoassay for the rapid detection of methicillin-resistant Staphylococcus aureus. J Med Microbiol (1998) 1.76
Production of monoclonal antibodies against human epithelial membrane antigen for use in diagnostic immunocytochemistry. Br J Cancer (1985) 1.76
Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer (2010) 1.74
Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res (1992) 1.74
Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. Cancer Res (1994) 1.72
Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol (2001) 1.71
Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat (1998) 1.70